Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Velcade plus dexamethasone versus VAD induction for newly diagnosed multiple myeloma
2005-000537-38Phase 3Completed
- Sponsor
- CHU de Nantes
- Start
- Sep 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bortezomib, dexamethasone, vincristine and doxorubicin in multiple myeloma (MM) (2 arms), sponsored by CHU de Nantes. Primary endpoints: Complete remission rate and Disappearance of monoclonal component in blood and urine. Started Sep 2006; status: completed.
02
Drugs
bortezomibdexamethasonevincristinedoxorubicin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2005-000537-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000537-38.